Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier organic anion transporter family member 6A1 (SLCO6A1)
- Target
- SLCO6A1
- Molecular classification
- Transporter, Solute carrier superfamily (SLC), Organic anion transporting polypeptide (OATP) family (SLCO subfamily)
01
Overview
SLCO6A1 is a member of the organic anion transporting polypeptides (OATPs), part of the solute carrier (SLC) superfamily, specifically the SLCO subfamily. It is predicted to function as a sodium-independent organic anion transporter and is primarily expressed in the testis, spleen, brain, and placenta. As a cancer/testis antigen designated CT48, it is selectively expressed in normal testis and in a variety of tumors, implicating a possible role in cancer biology or germ cell transporter functions. Unlike the major OATP members, SLCO6A1’s endogenous substrates, pharmacological interactions, and physiological roles are poorly characterized. The protein is predicted to have 12 transmembrane domains and is located in the plasma membrane, but very limited experimental evidence is available regarding its substrate specificity or clinical relevance as a drug transporter.
- Other names
- Organic anion-transporting polypeptide 6A1 (OATP6A1)SLC21A19OATP-IOATPYCancer/testis antigen 48 (CT48)Gonad-specific transporter (GST)Testis-specific organic anion transporterSolute carrier family 21 member 19MGC26949Testicular tissue protein Li 174
02
Mechanism of action
Not established specifically for SLCO6A1; generally, OATP family proteins mediate sodium-independent uptake of amphipathic organic anions, hormones, and drugs
03
Biological functions
Sodium-independent organic anion transportPredicted plasma membrane localization and possible involvement in transmembrane substrate exchange
04
Disease associations
Cancer (as a cancer/testis antigen, possible biomarker or involvement; specific roles remain unclear)Other (Uvula cancer and Inferolateral myocardial infarct have been associated, but evidence is limited in scope)
05
Safety considerations
Safety issues specific to SLCO6A1 as a therapeutic target are unknown due to lack of drug targeting and insufficient functional data; transporter family generally implicated in drug-drug interactions and altered pharmacokinetics if polymorphic or deregulated
06
Biomarkers
Cancer/testis antigen expression (CT48) in tumors may serve as a biomarker in research contexts; not established for clinical use
Beyond the preview
Go deeper on Solute carrier organic anion transporter family member 6A1 (SLCO6A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solute carrier organic anion transporter family member 6A1 (SLCO6A1).